Study finds potential in Dainippon Sumitomo anxiety drug

06/18/2009 | Reuters

A drug previously developed by Novartis and picked up by co-development partner Dainippon Sumitomo Pharma is showing promise as a fast-acting and safer treatment for anxiety, German researchers reported. The compound, labeled XBD173, affects the brain chemical GABA differently from Valium and other anxiety pills in such a way that it promotes the synthesis of neurosteroids that modulate the effects of GABA.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Director, Quality Regulatory Affairs
Cardinal Health
Chicago, IL
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC